Study of Atiprimod Treatment for Patients With Advanced Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00430014
Recruitment Status : Terminated (Sponsor Withdrew)
First Posted : February 1, 2007
Last Update Posted : February 15, 2012
Callisto Pharmaceuticals
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

Brief Summary:

Primary Objectives:

The primary objectives of this study are to identify the maximum tolerated dose (MTD) and to evaluate the safety of atiprimod when given in doses starting at 60 mg/day and ranging to 360 mg/day, or the MTD, whichever is lower, in patients with advanced cancer.

Secondary Objectives:

The secondary objectives of this study are to measure the pharmacokinetics of atiprimod and to evaluate the efficacy of atiprimod treatment in patients with advanced cancer, and to compare the pharmacokinetics of atiprimod tablets and capsules at the starting dose, with the intent of switching to capsules for the dose escalation if the capsules pose no safety issues.

Condition or disease Intervention/treatment Phase
Advanced Cancer Drug: Atiprimod Phase 1

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer
Study Start Date : March 2005
Actual Primary Completion Date : February 2012
Actual Study Completion Date : February 2012

Arm Intervention/treatment
Experimental: Atiprimod Drug: Atiprimod
Starting Dose of 60 mg/day orally for 14 days of 28 day cycle.

Primary Outcome Measures :
  1. Maximum Tolerated Dose (MTD) of Atiprimod [ Time Frame: With each 28 day (4 week) cycle ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   13 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patient must have histological proof of advanced cancer and must have failed or relapsed following standard therapy or have no standard therapy available.
  2. Patient must have an estimated life expectancy of at least 12 weeks.
  3. Patient must have measurable or evaluable disease.
  4. Patient has an ECOG (Zubrod) performance status of 0 to 2.
  5. Age >/= 13 years at the time of signing informed consent.
  6. All necessary screening evaluations for determining eligibility must be obtained within 14 days prior to the first dose of study drug except for measurement of disease extent, which can be obtained within 28 days prior to the first dose of study drug.
  7. Patient must be able to adhere to the study visit schedule and other protocol requirements.
  8. Patient must understand and voluntarily sign an informed consent document.
  9. Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test. In addition, sexually active WCBP must agree to use adequate contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner).

Exclusion Criteria:

  1. Renal insufficiency (serum creatinine levels >/= 2 times the upper limit of normal).
  2. Concomitant radiotherapy, chemotherapy, or other investigational agents/therapies.
  3. Peripheral neuropathy of Grade 3 or greater assessed by a directed neurologic examination, including light touch, pinprick, proprioception, and deep tendon reflexes of the upper and lower extremities; and questioning for symptoms of paresthesia and numbness (FACT/GOG-Ntx: Appendix D).
  4. Patients with evidence of clinically significant mucosal or internal bleeding. (For example, a decrease in hemoglobin of greater than 1.5 gm will be considered clinically significant.)
  5. Patients with a platelet count < 50,000 cells/mm^3.
  6. Patients with an absolute neutrophil count (ANC) of < 1000 cells/mm^3.
  7. ALT/SGPT or AST/SGOT levels >/= 2 times the upper limit of normal (ULN) except in patients with documented hepatic metastases.
  8. Total bilirubin > 2 times the ULN.
  9. Any condition which, in the opinion of the Investigator, places the patient at unacceptable risk if he/she were to participate in the study. Such examples include infection requiring hospitalization and psychiatric health which would make compliance understanding difficult.
  10. Clinically relevant active infection or serious co-morbid medical conditions such as recent (</6 months) MI, unstable angina, difficult to control CHF, uncontrolled HTN, difficult to control cardiac arrhythmias, COPD or chronic restrictive pulmonary disease, and cirrhosis. Examples of uncontrolled HTN and difficult to control cardiac arrhythmias include situations in which patients still have the problem while on medication or patients who have required > two medication changes in the last 6 months in order to control the problem, or cardiac patients with a NYHA classification of > Class II.
  11. If WCBP, pregnant, lactating, or not using adequate contraception.
  12. As atiprimod is a potent inhibitor of CYP2D6 (a chemical that is produced naturally by the body that processes and eliminates certain types of chemicals), patients taking drugs that are substrates of CYP2D6 (e.g., beta blockers, antidepressants, and antipsychotics; see Appendix G) will be excluded from the study.
  13. Received any form of radiotherapy, chemotherapy, or other investigational agents/therapies within 30 days prior to the first dose of study drug.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00430014

United States, Texas
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Callisto Pharmaceuticals
Principal Investigator: Razelle Kurzrock, MD M.D. Anderson Cancer Center

Additional Information:
Responsible Party: M.D. Anderson Cancer Center Identifier: NCT00430014     History of Changes
Other Study ID Numbers: 2004-0913
First Posted: February 1, 2007    Key Record Dates
Last Update Posted: February 15, 2012
Last Verified: February 2012

Keywords provided by M.D. Anderson Cancer Center:
Advanced Cancer
Guanylyl cyclase receptor antagonist

Additional relevant MeSH terms: